KT-1

**KT-1** is an investigational backbone-degradable diblock N-(2-hydroxypropyl)methacrylamide copolymer–epirubicin conjugate developed at the University of Utah. Also called 2P-EPI, it covalently incorporates epirubicin through a cathepsin-sensitive glycylphenylalanylleucylglycyl linker within a degradable HPMA copolymer architecture. The conjugate is designed to improve epirubicin pharmacokinetics and tumor retention while retaining anthracycline-mediated DNA damage and immunogenic cell death activity. In murine tumor models, KT-1 has promoted tumor infiltration and activation of CD8-positive T cells and has been evaluated alone and with the multivalent PD-L1 antagonist MPPA in melanoma, colorectal cancer, and breast cancer models. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7566519/))

Other names

2P-EPI